A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma
Open Access
- 1 January 2016
- journal article
- clinical trial
- Published by XMLink in Journal of Korean Medical Science
- Vol. 31 (12) , 1983-1988
Abstract
Kim SH, et al. J Korean Med Sci. 2016 Dec;31(12):1983-1988. https://doi.org/10.3346/jkms.2016.31.12.1983Keywords
Funding Information
- National Cancer Center (NCC 1041140-1)
- Pfizer
- Korean Urological Oncology Society (2010-0112)
This publication has 23 references indexed in Scilit:
- The Impact of Targeted Molecular Therapies on the Level of Renal Cell Carcinoma Vena Caval Tumor ThrombusEuropean Urology, 2011
- New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and Historical OverviewThe Oncologist, 2011
- Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell CarcinomaJournal of Clinical Oncology, 2010
- Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinibAnnals of Oncology, 2009
- Recent advances in molecular targeted therapy for metastatic renal cell carcinomaInternational Journal of Urology, 2009
- Response of the Primary Tumor to Neoadjuvant Sunitinib in Patients With Advanced Renal Cell CarcinomaJournal of Urology, 2009
- Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigmBJU International, 2008
- Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor ResponseClinical Cancer Research, 2008
- Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variableBritish Journal of Cancer, 2006
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993